Drug General Information (ID: DDI7SFPQMN)
Drug Name			Dofetilide		Drug Info		Grepafloxacin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiarrhythmic Agents				Antibiotics
Structure

Mechanism of Dofetilide-Grepafloxacin Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Dofetilide				Grepafloxacin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Dofetilide and Grepafloxacin

Recommended Action
Management		Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
2	Canadian Pharmacists Association.
3	Cerner Multum, Inc. "Australian Product Information.".
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5	Lode H, Vogel F, Elies W "Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance." Clin Ther 21 (1999): 61-74. [PMID: 10090425]
6	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
7	Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81. [PMID: 8838432]